Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Research & Development (2016 - 2025)

Enanta Pharmaceuticals' Research & Development history spans 14 years, with the latest figure at $20.9 million for Q4 2025.

  • For Q4 2025, Research & Development fell 24.58% year-over-year to $20.9 million; the TTM value through Dec 2025 reached $99.9 million, down 18.59%, while the annual FY2025 figure was $106.7 million, 18.81% down from the prior year.
  • Research & Development reached $20.9 million in Q4 2025 per ENTA's latest filing, down from $23.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $48.9 million in Q3 2021 to a low of $20.9 million in Q4 2025.
  • Average Research & Development over 5 years is $36.2 million, with a median of $36.3 million recorded in 2023.
  • Peak YoY movement for Research & Development: soared 35.5% in 2021, then plummeted 33.14% in 2024.
  • A 5-year view of Research & Development shows it stood at $48.5 million in 2021, then fell by 15.75% to $40.9 million in 2022, then fell by 11.08% to $36.4 million in 2023, then dropped by 23.96% to $27.7 million in 2024, then decreased by 24.58% to $20.9 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Research & Development are $20.9 million (Q4 2025), $23.8 million (Q3 2025), and $27.2 million (Q2 2025).